Traws Pharma Inc (TRAW) Stock Price, Quote & News

Latest News on TRAW

Jan 10, 2025, 5:55 PM EST - 7 days ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Dec 30, 2024, 8:00 AM EST - 18 days ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 23, 2024, 12:00 PM EST - 25 days ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 7:00 AM EST - 25 days ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Nov 14, 2024, 4:30 PM EST - 2 months ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Oct 8, 2024, 7:30 AM EDT - 3 months ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Sep 30, 2024, 7:30 AM EDT - 3 months ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 20, 2024, 7:30 AM EDT - 4 months ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 17, 2024, 4:05 PM EDT - 4 months ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Aug 20, 2024, 9:02 AM EDT - 5 months ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 15, 2024, 7:00 AM EDT - 5 months ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 14, 2024, 4:30 PM EDT - 5 months ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Apr 2, 2024, 7:15 AM EDT - 10 months ago

Traws Pharma Announces New Employee Inducement Grants

Mar 8, 2024, 8:00 AM EST - 11 months ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Dec 8, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Nov 28, 2023, 8:00 AM EST - 1 year ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 14, 2023, 8:18 PM EST - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 2, 2023, 10:37 AM EDT - 1 year ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Onconova Expands Leadership Team with Two Key Appointments

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 9:08 PM EDT - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Jun 14, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2023, 9:11 PM EDT - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:18 PM EDT - 1 year ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 4, 2023, 4:05 PM EDT - 1 year ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Apr 6, 2023, 4:05 PM EDT - 1 year ago

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Mar 23, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Mar 16, 2023, 9:56 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Mar 16, 2023, 4:04 PM EDT - 2 years ago

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

Mar 9, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Mar 7, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Feb 7, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Dec 19, 2022, 4:05 PM EST - 2 years ago

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

Dec 7, 2022, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

Nov 28, 2022, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

Nov 14, 2022, 8:54 PM EST - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 4:05 PM EST - 2 years ago

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

Nov 7, 2022, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022

Sep 22, 2022, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Sep 12, 2022, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Sep 1, 2022, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 11:14 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 4:05 PM EDT - 2 years ago

Market Cap	20.70M
Revenue (ttm)	230,000.00
Net Income (ttm)	-18.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8,239.13%
Debt to Equity Ratio	0.00

Volume	102,100
Avg Vol	666,500
Day's Range	N/A - N/A
Shares Out	3.03M
Stochastic %K	19%
Beta	1.13
Analysts	Strong Sell
Price Target	$6.00